Biogen deals the tau pipeline another blow
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Prilenia hopes to buck the Huntington’s trend
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
Biotech’s important clinical data readouts
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Semorinemab failure tempers tau hopes
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Contingent value is back in vogue
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
EHA 2020 – the sickle cell competition hots up
Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
Covid-19 adds a new danger to drug launches
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
For Lundbeck’s acquisition strategy bad luck comes in threes
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
